Tissue Regenix, which uses animal and human tissue to replace damaged human body parts, has signed seven regional sales distribution agreements ahead of the launch of its DermaPure brand in the US in early 2014.
York-based Tissue Regenix has high hopes for DermaPure, a human decellularised dermis product that can cure chronic wounds.
America is a key target market for the company as chronic wounds affect around 6.5 million patients in the US.
The seven agreements with regional distributors will represent over 40 sales representatives who will actively promote DermaPure into acute care hospitals, Veteran Affairs Hospitals and institutions, and Long Term Acute Care hospitals in the US.
The agreements will enable Tissue Regenix to promote DermaPure in Alaska, Washington, Oregon, Idaho, Utah, Montana, New Mexico, Arizona, Minnesota, North Dakota, South Dakota, Wisconsin, Illinois, Texas, Pennsylvania, New York, Maryland, New Jersey, Delaware, Massachusetts, Connecticut, Rhode Island, Vermont, Maine and New Hampshire.
Over time, Tissue Regenix plans to target all the US states and will sign further distribution agreements to give it sales coverage in all US metropolitan areas. DermaPure is on course to launch in the US during the first three months of 2014.